
News|Articles|December 8, 2010
ASH 2010 Homepage Header
Advertisement
Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.
- Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy
- Ofatumumab generates high response rates in refractory CLL
- Industry update: Early-stage trials establish pathways for new treatment agents
- More Coverage from ASH 2010
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients
5



































